Graham brings to Filamon a lifetime career in cancer research and drug development, along with a wealth of public company corporate experience spanning three decades in Australia, U.K. and U.S.

His Doctorate of Philosophy (Faculty of Medicine, The University of Sydney) was awarded for the manufacture of a novel immunosuppressive drug for the treatment of kidney transplant recipients. Twenty-two years of cancer research then followed, before the establishment of his first company, Novogen Limited (now Kazia Therapeutics), in 1994. That was followed by the establishment of an additional three exchange-listed biotechnology companies, at various times serving as Chairman, CEO and Director of all four companies, all of which currently remain operational.

• Novogen Ltd (now Kazia Therapeutics) (Nasdaq: KZIA) listed 1994
• MEI Pharma Inc (Nasdaq: MEIP) listed 2002
• Noxopharm Ltd (ASX: NOX) listed 2016
• Nyrada Inc (ASX: NYR) listed 2020

Both as a medical researcher and cancer survivor, Graham has made it his life’s mission to better understand the underlying mechanisms that allow cancers to survive and flourish in the body, on the basis that understanding those mechanisms is the critical step in finding effective treatments. It was the approaches being taken by Professors de Souza and Scott (role of inflammation in driving tumour aggression) that attracted him to become involved in Filamon.

From his first research posting at the University of Virginia, through his time as a Clinical Research Physician with Eli Lilly Australia, to his appointment as the Professor of Medical Oncology at Western Sydney University, and now Professor of Medicine at the University of Sydney at Nepean Cancer Centre, Paul’s focus has been on bridging the preclinical and clinical aspects of drug development. Known as the “Valley of Death” in pharma and biotech industry, taking a molecule through the clinic has been a major challenge and the cause of considerable financial heartache. Together with Professor Graham Kelly and Professor Kieran Scott, and the establishment of Filamon Limited, a new approach to the “Valley of Death” has been developed, with a streamlined process to fast-track new treatments for cancer.

From his first post-doctoral research posting in medicinal chemistry at the University College London, UK through his hands-on time as a R&D formulation chemist with Mayne Pharma Australia, to his various appointments in drug discovery, scale-up of drug manufacture, formulation and pharmaceutics and regulatory compliance, Philip’s passion and success has been based on assisting companies developing medicines in all phases of development to ensure they are formulated and manufactured to maximise their therapeutic efficiency, safety, and regulatory compliance while providing a commercial advantage.

Start-ups taking a molecule from discovery and pre-clinical phase into the clinic and out of the “valley of death” has been a major challenge and the cause of financial heartache at times. In teaming with the formidable, combined knowledge and experience of Professors Graham Kelly, Paul de Souza and Kieran Scott, and the establishment of Filamon Limited, a new approach has been developed to fast-track innovative treatments for cancer.

Currently Associate Professor, Oncology, Western Sydney University. Kieran has significant experience in multidisciplinary research across diverse research environments.

FLM-c2 is the results of over 30 years of work by Kieran in collaboration with over scientists and clinicians..

Kieran's past roles include President of the Australia Society of Medical Research, the National Health and Medical Research Council (NMHRC), and the Ingham Foundation.

Cameron is the Founding and Managing Director of Bio 101. A qualified Chartered Accountant, Cameron acts as CFO and Company Secretary for several ASX listed healthcare companies and Venture Capital investee companies.

Cameron has assisted clients in the IPO process and acts as Australian Resident Director for various subsidiaries of foreign companies.